Mohan Suntha, MD, MBA

BA:  Brown University, 1986

MD: Jefferson Medical College, 1990

Residency: University of Maryland School of Medicine, 1994

Clinical Oncology Fellow, American Cancer Society: University of Maryland School of Medicine-Head & Neck Malignancies, 1994-1995

MBA: Wharton School of Business at the University of Pennsylvania, 2009

Certification: American Board of Radiology(ABR).

Dr. Suntha joined the Department of Radiation Oncology at the University of Maryland School of Medicine as an Assistant Professor in 1995, after completing residency training in Radiation Oncology at University of Maryland School of Medicine. Dr. Suntha received his BA from Brown University in 1986 and his medical degree from Jefferson Medical College in 1990. He completed an internship in Internal Medicine at Bryn Mawr Hospital in Pennsylvania. In May, 2009, he earned an MBA from The Wharton School of Business at the University of Pennsylvania.

In 2019, Dr. Suntha was appointed President and CEO of the University of Maryland Medical System (UMMS). Prior to this, he has held numerous administrative roles within the UM Medical System and School of Medicine. He served as Vice Chair of the Department of Radiation Oncology, University of Maryland School of Medicine and the Associate Director of Clinical Affairs at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) where he is also the Marlene and Stewart Greenebaum Professor of Radiation Oncology. In 2009 he was appointed as the Vice President for System Program Development for UMMS. He was appointed as President and CEO of the University of Maryland’s St. Joseph Medical Center in December 2012. Then in May 2016, after a nationwide search, Dr. Suntha was appointed President and CEO of the University of Maryland Medical Center which included the Shock Trauma Center, Children’s Hospital and the Greenebaum Comprehensive Cancer Center as well as the Midtown Campus.

head, neck, head and neck, esophagus, esophageal, oropharyngeal, thoracic

Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234).

Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC.

Cancer. 2016 Jul 15. doi: 10.1002/cncr.30204. [Epub ahead of print]   PMID:27419843

Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.

Boggs DH, Hanna A, Burrows W, Horiba N, Suntharalingam M.

J Gastrointest Cancer. 2015 Jun;46(2):131-7. doi: 10.1007/s12029-015-9699-y.  PMID:25759174

Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck.

Shenouda G, Zhang Q, Ang KK, Machtay M, Parliament MB, Hershock D, Suntharalingam M, Lin A, Rotman M, Nabid A, Hong S, Shehata S, Cmelak AJ, Sultanem K, Le QT.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):907-15. doi: 10.1016/j.ijrobp.2014.12.018. Epub 2015 Feb 7.  PMID:25670542

State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Lin J, Kligerman S, Goel R, Sajedi P, Suntharalingam M, Chuong MD.

J Gastrointest Oncol. 2015 Feb;6(1):3-19. doi: 10.3978/j.issn.2078-6891.2014.062. Review.  PMID:25642333

Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Lubek JE, Schumaker LM, Cullen KJ.

Head Neck. 2016 Apr;38(4):564-72. doi: 10.1002/hed.23933. Epub 2015 Jun 30.  PMID:25488341